Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC

Immunome

Immunome

IMNM

0.00
  • Immunome dosed the first patient in a Phase 1, first-in-human study of IM-1617, an antibody-drug conjugate for advanced solid tumors.
  • No clinical results have been presented; the trial will assess safety and early signs of anti-tumor activity.
  • IM-1617 uses the company’s HC74 topoisomerase I inhibitor payload, extending its ADC platform into a new solid-tumor program.
  • Pipeline timing flagged for follow-on ADC candidates, with IND submissions planned for IM-1340 in mid-2026 and IM-1335 in late 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606110730BIZWIRE_USPR_____20260611_BW016477) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.